duke university‘s john hickey has been internationally recognized by nature magazine and Takeda Advancing the next generation of biomedical research and shortlisted for the 2026 Innovators in Science Award.
He was one of nine young researchers selected from among the record-breaking researchers. 315 posts from 47 countries and 230 institutions By an independent panel of judges convened by the Nature Awards.
The assessment was announced as part of Takeda and Nature’s official release of the 2026 Innovators in Science Award shortlist.
Takeda and Nature announce finalist list for 2026 Innovators in Science Award
The award supports emerging biomedical researchers around the world focused on gastrointestinal diseases, inflammatory diseases, neuroscience, and oncology.
London, January 21, 2026
Takeda and nature is pleased to announce the finalists for the 2026 Innovators in Science Award.
Established in 2016, this global award celebrates groundbreaking research focused on emerging scientific leaders who advance the frontiers of discovery and fuel innovations that can change lives.
As one of the largest awards of its kind, young researcherThe Innovators in Science Award strengthens Takeda’s commitment to promoting scientific excellence and fostering a culture of partnership between industry and academia.
“Young scientists often face limited resources and visibility at critical moments in their careers. Their ideas may be bold, but securing the support they need to realize breakthrough research can be difficult,” said Andrew Plump, MD, president of research and development at Takeda. “We take pride in recognizing up-and-coming scientists whose research is shaping the future of science. Through meaningful support such as funding, mentorship, and collaboration, we strive to strengthen their continued professional growth and impact.”
2026 Finalists by Therapeutic Area
The following nine young researchers were selected from a record 315 applications. 230 institutions in 47 countries By an independent panel of judges convened by the Nature Awards.
Gastrointestinal and inflammatory diseases
Tyler Huike, University of Michigan – For research investigating how the behavior of self-organizing cells shapes the structure of organs during development and regeneration.
Eye Ing Lim, princeton university – For research on maternal immune remodeling by studying how reproduction and early childhood development reprogram the intestinal immunity of mothers and their offspring.
Zhang Yankong, Chinese Academy of Agricultural Sciences – For her research applying AI-powered multi-omics to decipher the “dark matter” of the microbiome to identify new therapeutic targets for gastrointestinal and inflammatory diseases.
neuroscience
Christina Kim, princeton university – For research applying activity-dependent labeling techniques to study how cellular properties are disrupted in neuropsychiatric and neurological disorders.
bow penFudan University – Recognized in 2025 for driving the first clinical study of microglial replacement therapy, which opens new avenues for the treatment of neurological diseases.
Varun Venkataramani, Heidelberg University Hospital – For research at the intersection of neuroscience and oncology, and how synaptic neuron-tumor networks drive brain tumor progression.
oncology
Miriam Chalabi, Netherlands Cancer Institute – For her research aimed at improving short- and long-term outcomes for patients by developing innovative neoadjuvant immunotherapy approaches for non-metastatic cancer.
Jawad Fares, Northwestern University – For his work linking biological discoveries with clinical interventions for malignant brain tumors, laying the foundation for sophisticated, scalable, and sustainable treatments.
John Hickey, Duke University – For work creating next-generation spatial omics, imaging, biomaterials, and computational tools for mapping and manipulating multicellular interactions in tissues.
Commenting on the 2026 award shortlist: Alexia Ileana ZaromitidouNature Cancer Editor-in-Chief and this year’s Oncology Review Chair said:
“The Innovators in Science Award spotlights young researchers who are redefining what is possible in biomedical science. This year’s shortlist reflects extraordinary advances in gastrointestinal and inflammatory diseases, neuroscience and oncology – areas where innovation can truly change lives. At Nature, we are proud to celebrate these scientists and their commitment to advancing discovery.”
Winners in the three categories (one from each focus area) will be announced in February and will receive unlimited cash prizes. Prize money: $75,000. One grand prize winner will receive an additional prize, which will be announced live at the Innovators in Science Award Ceremony on April 9, 2026. $175,000 Awards, total grand prize $250,000. In addition, all finalists will undergo a 12-month career development program run by Nature. This program is designed to build skills and address the unique challenges and opportunities faced by emerging scientific leaders.
About the Innovators in Science Award
Released in 2016, Takeda Scientific Innovators Award We provide scientific leaders with the support and recognition they need to drive bold, innovative breakthroughs in their fields. Since its inception, the award has recognized the outstanding contributions of 10 established young researchers with $2 million in unrestricted funding. This global award recognizes researchers who are advancing the frontiers of scientific discovery and fostering innovations that have the potential to change lives. In 2026, the Innovators in Science Award will recognize groundbreaking research by young scientists in gastrointestinal and inflammatory diseases, neuroscience, and oncology. For more information, please visit: here.
About Takeda
Takeda is committed to creating better health for people and a brighter future for the world. We aim to discover and deliver life-changing treatments in our core therapeutic and business areas including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance new frontiers of treatment options through our dynamic and diverse pipeline. As a leading, values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, people and the planet. Our employees in nearly 80 countries and territories are driven by our purpose and grounded in the values that have defined our company for more than two centuries. For more information, please visit: here.
About Nature Portfolio
Nature Portfolio’s high-quality products and services span the life, physical, chemical, and applied sciences and are dedicated to serving the scientific community.
Nature (founded in 1869) is the world’s leading weekly science magazine. Nature Portfolio is also home to open access journals, including the Nature Research and Nature Reviews journals, the leading open access multidisciplinary journal Nature Communications, and Scientific Reports. Together, these journals publish some of the world’s most important scientific discoveries.
Online at Nature.com, we serve Nature Portfolio content, including news and commentary from Nature and the leading science job site Nature Careers, to more than 9 million unique visitors each month. Nature Portfolio also offers a range of researcher services, including online and in-person training, and expert language and editing services. For more information, visit nature.com and follow Nature. The Nature portfolio is part of Springer Nature.
You can also read:
John Hickey: Thrilled to be selected as V Foundation Scholar Award recipient